Art

J-GLOBAL ID：201502281908666800   Reference number：15A0454392

Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest

リゴサチブは骨髄異形成症候群由来の株化細胞の死をDNAダメージによるG2/M停止によって誘導する

Author (7)： HYODA Tomoko (Div. of Medical Technol., Kawasaki Coll. of Allied Health Professions, Okayama, Japan; Dep. of Medical Technol. ...) ,  TSUJIOKA Takayuki ,  NAKAHARA Takako ,  SUEMORI Shin-ichiro ,  OKAMOTO Shuichiro ,  KATAOKA Mikio ,  TOHYAMA Kaoru
Material： Cancer Science (Web)  (Cancer Sci (Web))
Volume： 106  Issue： 3  Page： 287-293  Publication year： Mar. 2015 
JST Material Number： U0505A  ISSN： 1349-7006  Document type： Article
Article type： 原著論文  Country of issue： United States (USA)  Language： ENGLISH (EN)

Thesaurus term： *myelodysplastic syndrome ,...
Semi thesaurus term： MDS-L細胞 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=15A0454392&from=J-GLOBAL&jstjournalNo=U0505A") }}

JST classification (5)： Basic research of enzyme preparations and enzyme inhibitor preparations  (GW21010W) ,  Basic research of antitumor(=antineoplastic)drugs  (GW16010A) ,  Basic oncology in general  (GE02010R) ,  Basic hematology  (GK01020N) ,  Blood cell tumors(=neoplasms)  (GK04000M)

Substance index (1)： Rigosertib

Reference (34)：

• Brunning RD, Orazi A, Germing U, et al. “Myelodysplastic Syndrome/Neoplasms, Overview”. In: Swerdlow SH, Campo E, Harris NL et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 6th edn. Lyon: IARC, 2008; 87-107.
• Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-99.
• Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454-65.
• Quintás-Cardama A, Santos FP, Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 2010; 7: 433-44.
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. International Vidaza High-Risk MDS Survival Study Group Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-32.

Terms in the title (6)： 骨髄異形成症候群 ,  株化細胞 ,  死 ,  DNA ,  ダメージ ,  誘導